Targeted Augmentation News Today

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...

– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the...

-- Stoke Therapeutics late Tuesday disclosed plans to sell up to $75 million of its common shares through a public stock offering, subject to market and other conditions. The biotechnology company...

-- Stoke Therapeutics shares were up 68% in recent Tuesday trading, a day after the company reported its investigational new medicine STK-001 was found to benefit subjects with Dravet syndrome, a...

-- Stoke Therapeutics has an average buy rating and price target range of $13 to $35, according to analysts polled by Capital IQ. Price: 11.54, Change: +5.04, Percent Change: +77.54 ...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a...

– As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 – ...